Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

N21: The interpretation of thiopurine metabolites in clinical practice: IBD nurses experience in three North West England NHS trusts

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Campbell*1, E. Nelson2, S. Kari2, J. Hocking3, T. Hickey3

1Stockport Foundation NHS Trust, Gastroenterology, Stockport, UK, 2Macclesfield District General Hospital, Gastroenterology, Macclesfield, UK, 3Royal Blackburn Hospital, Gastroenterology, Blackburn, UK

Files: 1
N22: Audit into initial response to vedolizumab infusions for IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Lloyd-Ford*1, M. Gordon1

1Aneurin Bevan University Health Board, Gastroenterology Ambulatory Unit, Newport, UK

N23: IBD patients experience of the care given at the Stockholm Gastro Centre

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Jäghult*1,2, S. Soto Villagran2, S. Pengel2, L. Niculae2

1Karolinska Institutet Danderyd Hospital, Department of Clinicla Science, Stockholm, Sweden, 2GHP Stockholm Gastro Center, Stockholm, Sweden

Files: 1
N24: Experience with Ustekinumab (STELARA®) in Paediatric inflammatory bowel disease (pIBD) – A case series

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Buckingham*1, S. Sider1, L. Cococcioni1, A. ElZein1, S. Chadokufa1, N. Shah1, A. Ocholi1, O. Borrelli1, F. Kiparissi1

1Great Ormond Street Hospital, Gastroenterology, London, UK

Files: 1
OP01: In-depth characterisation of host genetics and gut microbiome unravels novel host–microbiome interactions in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Hu*1, A. Vich Vila1, R. Gacesa1, V. Collij1, R. Xavier2, C. Stevens3, M. Daly3, C. Wijmenga4, H. van Dullemen1, G. Dijkstra1, M. Visschedijk1, E. Festen1, J. Fu5, A. Kurilshikov4, A. Zhernakova4, R. Weersma1

1Universitair Medisch Centrum Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 2Massachusetts General Hospital, Molecular Biology, Boston, MA, USA, 3Broad Institute, Boston, MA, USA, 4Universitair Medisch Centrum Groningen, Genetics, Groningen, The Netherlands, 5Universitair Medisch Centrum Groningen, Pediatrics, Groningen, The Netherlands

OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Li*1, J. Kuemmerle1

1Virginia Commonwealth University, Internal Medicine, Richmond, VA, USA

OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Cosin-Roger*1,2, D. Ortiz-Masia3, F. Canet1, A. Trescoli-Garcia1, S. Calatayud1, M. D. Barrachina1

1University of Valencia, Pharmacology, Valencia, Spain, 2Hospital Dr Peset, Valencia, Spain, 3University of Valencia, Medicine, Valencia, Spain

OP04: Turning sweet in inflammatory bowel disease: glycans as novel immunomodulators of T-cell-mediated immune response

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Dias1, M. Pereira1, A. Correia1, I. Alves1, V. Pinto1, L. Azevedo2, L. Maia3, R. Marcos-Pinto3, M. Vilanova1, P. Lago3, S. Pinho*1

1Institute for Research and Innovation in Health (i3S), Immunology, Cancer and GlycoMedicine, Porto, Portugal, 2Medical Faculty, Department of Community Medicine, Information and Health Decision Sciences, Porto, Portugal, 3Porto Centre Hospital, Gastroenterology, Porto, Portugal

OP05: Crohn’s disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in mild-to-moderate active paediatric Crohn’s disease: a prospective randomised controlled trial

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Van Limbergen1,2, E. Wine3, A. Assa4, R. Sigall Boneh5, R. Shaoul6, M. Kori7, S. Cohen8, S. Peleg9, H. Shamaly10, A. On11, P. Milman12, L. Abramas5, T. Ziv Baran13, S. Grant14, A. Levine*5,13

1Dalhousie University, Halifax, Canada, 2IWK Center, Halifax, Canada, 3University Alberta, Edmonton, Canada, 4Schneider Medical Center, Petach Tikva, Israel, 5Wolfson Medical Center, Holon, Israel, 6Meyer Hospital, Haifa, Israel, 7Kaplan Hospital, Rehovot, Israel, 8Dana Childrens Hospital, Tel Aviv, Israel, 9HaEmek Hospital, Afula, Israel, 10French Hospital, Nazareth, Israel, 11Poriah Hospital, Tiberias, Israel, 12Hadassah Hospital, Jerusalem, Israel, 13Tel Aviv University, Tel Aviv, Israel, 14Mount Saint Vincent University, Halifax, Canada

OP06: Gut–brain axis revisited: Shedding light on the mucosa-associated microbial composition in IBD patients with psychological distress, anxiety, and depression

ECCO '19 Copenhagen

Year: 2019
Authors:

F. Humbel1, P. Juillerat2, M. Scharl1, B. Misselwitz2, P. Schreiner1, A. Macpherson2, G. Rogler1, R. von Känel3, B. Yilmaz4, L. Biedermann*1

1University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, 2Bern University Hospital, Department of Visceral Surgery and Medicine Bern, Switzerland, 3University Hospital Zurich, Consultation-Liaison Psychiatry and Psychosomatic Medicine, Zurich, Switzerland, 4University of Bern, Maurice Müller Laboratories, Bern, Switzerland

OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn’s disease due to autophagy impairment

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Gul1, E. Jones1,2, Z. Matthews3, P. Sudhakar1,2,4, A. Treveil1,2, D. Divekar2,3, J. Buck3, M. Jefferson3, S. Armstrong5, A. Watson2,3, S. Carding2,3, U. Mayer6, P. Powell3, I. Hautefort1, T. Wileman2,3, T. Korcsmaros*1,2

1Earlham Institute, Norwich, UK, 2Quadram Institute, Norwich, UK, 3Norwich Medical School, University of East Anglia, Norwich, UK, 4KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 5University of Liverpool, National Institute of Health Research, Liverpool, UK, 6School of Biological Sciences, University of East Anglia, Norwich, UK

OP08: Long-term efficacy and pharmacodynamics of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s disease: the OPERA II study

ECCO '19 Copenhagen

Year: 2019
Authors:

G. D’Haens*1, W. Reinisch2, S. D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D. I. Park9, X. Hébuterne10, K. J. Gorelick11, S. W. Martin12, A. Banerjee12, P. Nagy13, Y. Wang14, F. Cataldi14, W. J. Sandborn15

1Academic Medical Centre, Amsterdam, The Netherlands, 2Medical University of Vienna, Vienna, Austria, 3University of Washington, Seattle, WA, USA, 4Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 5University Hospital of Liège, Liège, Belgium, 6Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 7University Hospital Ulm, Ulm, Germany, 8University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany, 9Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, 10University of Nice Sophia Antipolis, Hospital l’Archet, Nice, France, 11Zymo Consulting Group, Newtown Square, PA, USA, 12Pfizer, Cambridge, MA, USA, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, USA, 15University of California San Diego, La Jolla, CA, USA

OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Peyrin-Biroulet*1, J. Panés2, M. Chiorean3, J. Zhang4, S. Vermeire5, V. Jairath6, A. Yarur7, C. Cabell4, S. Naik4, W. J. Sandborn8

1University Hospital of Nancy, Vandœuvre-lès-Nancy, France, 2Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3Virginia Mason Medical Center, Seattle, USA, 4Arena Pharmaceuticals, Inc., San Diego, USA, 5University Hospitals Leuven, Leuven, Flanders, Belgium, 6Western University, London, Ontario, Canada, 7Medical College of Wisconsin, Milwaukee, USA, 8University of California San Diego, La Jolla, USA

OP10: Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Brooks*1,2, D. Modos3, P. Sudhakar4,5, D. Fazekas4,6, A. Zoufir3, A. Watson1,7, M. Tremelling1, B. Verstockt8, S. Vermeire8, A. Bender3, S. Carding2,7, T. Korcsmaros2,4

1Norfolk and Norwich University Hospital, Gastroenterology, Norwich, UK, 2The Quadram Institute Bioscience, Gut Microbes and Health Programs, Norwich, UK, 3Centre for Molecular Science Informatics, Department of Chemistry University of Cambridge, Cambridge, UK, 4Earlham Institute, Norwich Research Park, Norwich, UK, 5KU Leuven,, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 6Eötvös Loránd, Department of Genetics, Budapest, Hungary, 7University of East Anglia, Norwich Medical School, Norwich, UK, 8University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

OP11: Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during ex vivo culture

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Arnauts*1,2, B. Verstockt1,3, M. Vancamelbeke1, S. Vermeire1,3, C. Verfaillie2, M. Ferrante1,3

1KU Leuven, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, 2KU Leuven, Department of Development and Regeneration, Leuven, Belgium, 3KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

OP12: Targeting inflammation in ulcerative colitis by inhibiting glucose uptake

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Gropp*1, H. Jodeleit1, J. Caesar1, C. Villarroel Aguilera1, F. Beigel2,3, S. Breiteneicher3, J. Stallhofer3, M. Siebeck1

1Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, 2Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, 3Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany

OP13: Molecular response to ustekinumab in moderate-to-severe ulcerative colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI Phase 3 induction study

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Li*1, F. Yang1, K. Hayden1, D. Strawn1, E. Wadman1, S. Bhagat1, C. Marano1, J. R. Friedman1

1Janssen Research and Development, LLC, Spring House, USA

OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1,1, S. Schreiber2, S. D. Lee3, J. O. Lindsay4, X. Hebuterne5, W. Zhou6, F. Cataldi6, A. P. Lacerda6, B. Huang6, W. Xie6, E. V. Loftus Jr7

1University of California San Diego, La Jolla, USA, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3University of Washington, Seattle, USA, 4Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK, 5Service de Gastroentérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France, 6AbbVie Inc., North Chicago, USA, 7Mayo Clinic, Rochester, USA

OP15: Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Burisch*1, H. Vardi2, D. Schwartz3, Z. Krznaric4, P. L. Lakatos5, M. Fumery6, L. Kupcinskas7, F. Magro8, E. Belousova9, P. Oksanen10, N. Arebi11, E. Langholz12, S. Turcan13, R. D’Inca14, V. Hernandez15, D. Valpiani16, Z. Vegh5, M. Giannotta17, K. H. Katsanos18, D. Duricova19, K. R. Nielsen20, H. A. L. Kievit21, P. Ellul22, R. Salupere23, A. Goldis24, I. Kaimakliotis25, N. Pedersen26, V. Andersen27, J. Halfvarson28, S. Sebastian29, J. F. Dahlerup30, P. Munkholm1, S. Odes3, Epi-IBD

1North Zealand University Hospital, Frederikssund, Denmark, 2Ben Gurion University of the Negev, Beer Sheva, Israel, 3Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, 4University Hospital Center Zagreb, Zagreb, Croatia, 5Semmelweis University, Budapest, Hungary, 6Amiens University and Hospital, Amiens, France, 7Lithuanian University of Health Sciences, Kaunas, Lithuania, 8Hospital de São João, Porto, Portugal, 9Moscow Regional Research Clinical Institute, Moscow, Russian Federation, 10Tampere University Hospital, Tampere, Finland, 11Imperial College London, London, UK, 12Herlev University Hospital, Herlev, Denmark, 13State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova, Republic of, 14Azienda Ospedaliera di Padova, Padova, Italy, 15Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 16Morgagni Hospital, Forli, Italy, 17Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, 18University Hospital, Ioannina, Greece, 19Charles University, Prague, Czech Republic, 20National Hospital of the Faroe Islands, Torshavn, Faroe Islands, 21Herning Hospital, Herning, Denmark, 22Mater Dei Hospital, Msida, Malta, 23Tartu University Hospital, Tartu, Estonia, 24University of Medicine ‘Victor Babes’, Timisoara, Romania, 25American Gastroenterology center, Nicosia, Cyprus, 26Slagelse Hospital, Department of medicine, Denmark, 27Regional Hospital of Viborg, Viborg, Denmark, 28Örebro University, Örebro, Sweden, 29Hull and East Yorkshire NHS Trust, Hull, UK, 30Aarhus University Hospital, Aarhus, Denmark

OP16: A randomised, multi-centre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild-to-moderate ulcerative colitis: efficacy results

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Bloom*1, T. Iqbal2, C. Nwokolo3, M. Smith4, D. O’Donoghue5, J. Hall6, B. Dzyngel6

1University College London Hospitals, London, UK, 2Queen Elizabeth Hospital Birmingham, Birmingham, UK, 3University Hospital Coventry and Warwickshire, Coventry, UK, 4Shrewsbury and Telford Hospital, Shrewsbury, UK, 5St Vincent’s University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 6Sublimity Therapeutics, Solana Beach, USA